Skip to content
Screener

McKesson MCK Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$42K-93.9%
Viatris logo
ViatrisVTRS
$700K0.0%
TOI
TOITOI
$21K-84.7%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$12.09M+3,405%
Doximity logo
DoximityDOCS
$3.08M+28.4%
Merck & Co. logo
Merck & Co.MRK
$43M+258%

Other financials

Income statement

See full
Revenue$105.38B+7.7%
Gross profit$3.7B+12.4%
Operating income$1.3B+27.3%
Net income$614.0M-21.7%
EPS (diluted)$5.15-17.6%

Balance sheet

See full
Cash & equivalents$5.3B+95.9%
Total debt$13.0B+15.7%
Total equity-$4.2B-116%
Total assets$88.3B+8.6%

Cash flow

See full
Operating cash flow-$220.0M+76.0%
CapEx$112.0M+0.9%
Free cash flow-$332.0M+67.7%

Valuation

See full
Market cap$102.7B+15.6%
Enterprise value$110.42B+13.4%
P/E22.4×-5.7×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%+0.1pp
Operating margin1.6%+0.4pp
Net margin1.1%+0.3pp
FCF margin1.6%0.0pp

Returns & leverage

See full
Return on equity36%
Debt / equity
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The source filing: McKesson’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:29 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000927653-26-000234
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025
Proceeds from issuances of long-term debt3,2151,990
Repayments of long-term debt(1)
Common stock transactions:
Issuances2322
Share repurchases(2,530)(581)
Dividends paid(102)(90)
Sale of noncontrolling interest in Medical-Surgical Solutions, net1,238
Other(211)(165)

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is McKesson's stock issuance proceeds?
McKesson (MCK) reported stock issuance proceeds of $23M in Q2 2026.
How has McKesson's stock issuance proceeds changed year-over-year?
McKesson's stock issuance proceeds increased by 4.5% year-over-year, from $22M to $23M.
What is the long-term trend for McKesson's stock issuance proceeds?
Over 3 years (2022 to 2025), McKesson's stock issuance proceeds has grown at a -22.9% compound annual growth rate (CAGR), from $220M to $101M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about McKesson's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude